BIO Coffee Chat: Price Controls Like MFN Harm Access, Increase Costs

Why It Matters

These policy missteps threaten both patient affordability and the pipeline of innovative biotech treatments, potentially slowing market entry of life‑saving therapies.

Key Takeaways

• IRA’s $2,100 Medicare out‑of‑pocket cap fails to lower patient costs
• MFN‑type pricing proposals could raise out‑of‑pocket spending and restrict access
• Plans respond to caps with higher premiums, deductibles, and tighter formularies
• International price controls rely on QALY metrics that devalue chronic disease therapies
• Patient advocates warn GUARD model may limit orphan‑drug availability

Pulse Analysis

The Inflation Reduction Act’s $2,100 Medicare out‑of‑pocket cap was marketed as a consumer‑friendly safeguard, yet early data reveal a paradoxical rise in patient expenses. By shifting cost sharing from flat co‑pays to higher co‑insurance rates and inflating deductibles, insurers have absorbed the cap’s protection while passing additional burdens onto beneficiaries. A MAPRx report released for 2026 shows beneficiaries confronting steeper premiums, reduced plan choices, and more aggressive formulary management, effectively neutralizing the intended affordability gains. S.

drug prices to those negotiated abroad. While the premise promises lower list prices, advocates warn that the approach could backfire by prompting insurers to tighten utilization management, raise co‑insurance, and exclude high‑cost orphan or protected‑class therapies. S. under MFN rules.

The convergence of these policies threatens both patient access and the biotech innovation pipeline. Higher out‑of‑pocket burdens can drive patients into debt, delay treatment initiation, and reduce real‑world evidence that manufacturers rely on for regulatory approvals. At the same time, manufacturers may hesitate to launch breakthrough therapies in a market where price caps and MFN constraints erode revenue potential. Patient‑advocacy groups like MAPRx and the Lupus Foundation are urging a balanced reform that safeguards affordability without compromising access, emphasizing transparent pricing, patient‑centered value assessments, and safeguards for orphan‑drug development.